Background:

sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].

Treatment with sn-Glycero-3-phosphocholine (Choline Alfoscerate) (250 mg/kg; i.m.; daily for 3 weeks) after seizure can improve seizure-induced cognitive impairment[2].sn-Glycero-3-phosphocholine (Choline Alfoscerate) increases the release of acetylcholine in rat hippocampus, facilitates learning and memory in experimental animals, improves brain transduction mechanisms and decreases age-dependent structural changes occurring in rat brain areas involved in learning and memory[3].

参考文献:
[1]. Traini E, et al. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipidwith a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9.
[2]. Traini E, et al. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipidwith a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9.
[3]. Lee SH, et al. Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. Brain Res. 2017 Jan 1;1654(Pt A):66-76.